Tinzaparin - Clinical Resources
Transitioning to Tinzaparin - Effective September 27, 2022
- All SHA sites transitioned to using tinzaparin as the low molecular weight heparin (LMWH) for most indications. Simultaneously, there was a switch to using enoxaparin REDESCA (a biosimilar agent) for the remaining indications.
Related Resources
Learning Module - Transitioning to Tinzaparin
-
Learning Modules Online Access Instructions - Search by Title
-
Transition to Tinzaparin - A Provincial Approach
-
ALERT: Log in to MyConnection prior to accessing any learning module to ensure completion is recorded in the system.
Implementation Resource
Learning Modules
-
Learning Modules Online Access Instructions - Search by CS-LM number or title
-
Transitioning to Tinzaparin for Hemodialysis Circuit Patency (CS-LM-0072)
-